Statements (19)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Takeda_Pharmaceuticals_International_AG
|
gptkbp:aims_to |
treat autoimmune diseases
treat organ transplant rejection |
gptkbp:ceo |
gptkb:Michael_A._Mc_Garrity
|
gptkbp:clinical_trial |
ongoing
|
gptkbp:collaborates_with |
research institutions
|
gptkbp:develops |
Talaris Therapeutics' lead product candidate
|
gptkbp:focuses_on |
gptkb:drug
|
gptkbp:founded |
gptkb:2018
|
gptkbp:headquarters |
gptkb:Nashville,_Tennessee
|
https://www.w3.org/2000/01/rdf-schema#label |
Talaris Therapeutics
|
gptkbp:investment |
venture capital firms
|
gptkbp:partnerships |
various academic institutions
|
gptkbp:research_focus |
immune tolerance
|
gptkbp:stock_exchange |
gptkb:battle
|
gptkbp:technology |
Talaris' proprietary technology platform
|
gptkbp:website |
www.talaristx.com
|